Cargando…

Extracellular volume quantification in isolated hypertension - changes at the detectable limits?

BACKGROUND: Diffuse myocardial fibrosis (DMF) is important in cardiovascular disease, however until recently could only be assessed by invasive biopsy. We hypothesised that DMF measured by T1 mapping is elevated in isolated systemic hypertension. METHODS: In a study of well-controlled hypertensive p...

Descripción completa

Detalles Bibliográficos
Autores principales: Treibel, Thomas A., Zemrak, Filip, Sado, Daniel M., Banypersad, Sanjay M., White, Steven K., Maestrini, Viviana, Barison, Andrea, Patel, Vimal, Herrey, Anna S., Davies, Ceri, Caulfield, Mark J., Petersen, Steffen E., Moon, James C.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2015
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4534050/
https://www.ncbi.nlm.nih.gov/pubmed/26264919
http://dx.doi.org/10.1186/s12968-015-0176-3
_version_ 1782385403558363136
author Treibel, Thomas A.
Zemrak, Filip
Sado, Daniel M.
Banypersad, Sanjay M.
White, Steven K.
Maestrini, Viviana
Barison, Andrea
Patel, Vimal
Herrey, Anna S.
Davies, Ceri
Caulfield, Mark J.
Petersen, Steffen E.
Moon, James C.
author_facet Treibel, Thomas A.
Zemrak, Filip
Sado, Daniel M.
Banypersad, Sanjay M.
White, Steven K.
Maestrini, Viviana
Barison, Andrea
Patel, Vimal
Herrey, Anna S.
Davies, Ceri
Caulfield, Mark J.
Petersen, Steffen E.
Moon, James C.
author_sort Treibel, Thomas A.
collection PubMed
description BACKGROUND: Diffuse myocardial fibrosis (DMF) is important in cardiovascular disease, however until recently could only be assessed by invasive biopsy. We hypothesised that DMF measured by T1 mapping is elevated in isolated systemic hypertension. METHODS: In a study of well-controlled hypertensive patients from a specialist tertiary centre, 46 hypertensive patients (median age 56, range 21 to 78, 52 % male) and 50 healthy volunteers (median age 45, range 28 to 69, 52 % male) underwent clinical CMR at 1.5 T with T1 mapping (ShMOLLI) using the equilibrium contrast technique for extracellular volume (ECV) quantification. Patients underwent 24-hours Automated Blood Pressure Monitoring (ABPM), echocardiographic assessment of diastolic function, aortic stiffness assessment and measurement of NT-pro-BNP and collagen biomarkers. RESULTS: Late gadolinium enhancement (LGE) revealed significant unexpected underlying pathology in 6 out of 46 patients (13 %; myocardial infarction n = 3; hypertrophic cardiomyopathy (HCM) n = 3); these were subsequently excluded. Limited, non-ischaemic LGE patterns were seen in 11 out of the remaining 40 (28 %) patients. Hypertensives on therapy (mean 2.2 agents) had a mean ABPM of 152/88 mmHg, but only 35 % (14/40) had left ventricular hypertrophy (LVH; LV mass male > 90 g/m(2); female > 78 g/m(2)). Native myocardial T1 was similar in hypertensives and controls (955 ± 30 ms versus 965 ± 38 ms, p = 0.16). The difference in ECV did not reach significance (0.26 ± 0.02 versus 0.27 ± 0.03, p = 0.06). In the subset with LVH, the ECV was significantly higher (0.28 ± 0.03 versus 0.26 ± 0.02, p < 0.001). CONCLUSION: In well-controlled hypertensive patients, conventional CMR discovered significant underlying diseases (chronic infarction, HCM) not detected by echocardiography previously or even during this study. T1 mapping revealed increased diffuse myocardial fibrosis, but the increases were small and only occurred with LVH.
format Online
Article
Text
id pubmed-4534050
institution National Center for Biotechnology Information
language English
publishDate 2015
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-45340502015-08-19 Extracellular volume quantification in isolated hypertension - changes at the detectable limits? Treibel, Thomas A. Zemrak, Filip Sado, Daniel M. Banypersad, Sanjay M. White, Steven K. Maestrini, Viviana Barison, Andrea Patel, Vimal Herrey, Anna S. Davies, Ceri Caulfield, Mark J. Petersen, Steffen E. Moon, James C. J Cardiovasc Magn Reson Research BACKGROUND: Diffuse myocardial fibrosis (DMF) is important in cardiovascular disease, however until recently could only be assessed by invasive biopsy. We hypothesised that DMF measured by T1 mapping is elevated in isolated systemic hypertension. METHODS: In a study of well-controlled hypertensive patients from a specialist tertiary centre, 46 hypertensive patients (median age 56, range 21 to 78, 52 % male) and 50 healthy volunteers (median age 45, range 28 to 69, 52 % male) underwent clinical CMR at 1.5 T with T1 mapping (ShMOLLI) using the equilibrium contrast technique for extracellular volume (ECV) quantification. Patients underwent 24-hours Automated Blood Pressure Monitoring (ABPM), echocardiographic assessment of diastolic function, aortic stiffness assessment and measurement of NT-pro-BNP and collagen biomarkers. RESULTS: Late gadolinium enhancement (LGE) revealed significant unexpected underlying pathology in 6 out of 46 patients (13 %; myocardial infarction n = 3; hypertrophic cardiomyopathy (HCM) n = 3); these were subsequently excluded. Limited, non-ischaemic LGE patterns were seen in 11 out of the remaining 40 (28 %) patients. Hypertensives on therapy (mean 2.2 agents) had a mean ABPM of 152/88 mmHg, but only 35 % (14/40) had left ventricular hypertrophy (LVH; LV mass male > 90 g/m(2); female > 78 g/m(2)). Native myocardial T1 was similar in hypertensives and controls (955 ± 30 ms versus 965 ± 38 ms, p = 0.16). The difference in ECV did not reach significance (0.26 ± 0.02 versus 0.27 ± 0.03, p = 0.06). In the subset with LVH, the ECV was significantly higher (0.28 ± 0.03 versus 0.26 ± 0.02, p < 0.001). CONCLUSION: In well-controlled hypertensive patients, conventional CMR discovered significant underlying diseases (chronic infarction, HCM) not detected by echocardiography previously or even during this study. T1 mapping revealed increased diffuse myocardial fibrosis, but the increases were small and only occurred with LVH. BioMed Central 2015-08-12 /pmc/articles/PMC4534050/ /pubmed/26264919 http://dx.doi.org/10.1186/s12968-015-0176-3 Text en © Treibel et al. 2015 Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
spellingShingle Research
Treibel, Thomas A.
Zemrak, Filip
Sado, Daniel M.
Banypersad, Sanjay M.
White, Steven K.
Maestrini, Viviana
Barison, Andrea
Patel, Vimal
Herrey, Anna S.
Davies, Ceri
Caulfield, Mark J.
Petersen, Steffen E.
Moon, James C.
Extracellular volume quantification in isolated hypertension - changes at the detectable limits?
title Extracellular volume quantification in isolated hypertension - changes at the detectable limits?
title_full Extracellular volume quantification in isolated hypertension - changes at the detectable limits?
title_fullStr Extracellular volume quantification in isolated hypertension - changes at the detectable limits?
title_full_unstemmed Extracellular volume quantification in isolated hypertension - changes at the detectable limits?
title_short Extracellular volume quantification in isolated hypertension - changes at the detectable limits?
title_sort extracellular volume quantification in isolated hypertension - changes at the detectable limits?
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4534050/
https://www.ncbi.nlm.nih.gov/pubmed/26264919
http://dx.doi.org/10.1186/s12968-015-0176-3
work_keys_str_mv AT treibelthomasa extracellularvolumequantificationinisolatedhypertensionchangesatthedetectablelimits
AT zemrakfilip extracellularvolumequantificationinisolatedhypertensionchangesatthedetectablelimits
AT sadodanielm extracellularvolumequantificationinisolatedhypertensionchangesatthedetectablelimits
AT banypersadsanjaym extracellularvolumequantificationinisolatedhypertensionchangesatthedetectablelimits
AT whitestevenk extracellularvolumequantificationinisolatedhypertensionchangesatthedetectablelimits
AT maestriniviviana extracellularvolumequantificationinisolatedhypertensionchangesatthedetectablelimits
AT barisonandrea extracellularvolumequantificationinisolatedhypertensionchangesatthedetectablelimits
AT patelvimal extracellularvolumequantificationinisolatedhypertensionchangesatthedetectablelimits
AT herreyannas extracellularvolumequantificationinisolatedhypertensionchangesatthedetectablelimits
AT daviesceri extracellularvolumequantificationinisolatedhypertensionchangesatthedetectablelimits
AT caulfieldmarkj extracellularvolumequantificationinisolatedhypertensionchangesatthedetectablelimits
AT petersensteffene extracellularvolumequantificationinisolatedhypertensionchangesatthedetectablelimits
AT moonjamesc extracellularvolumequantificationinisolatedhypertensionchangesatthedetectablelimits